Stockreport

Disc Medicine Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Disc Medicine, Inc.  (IRON) 
PDF Pursuing a traditional approval path for bitopertin in erythropoietic protoporphyria (EPP); Phase 3 APOLLO study is expected to complete enrollment in March 2026 with to [Read more]